Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 3
1997 3
1998 5
1999 1
2001 3
2002 6
2003 5
2004 12
2005 11
2006 16
2007 26
2008 23
2009 25
2010 28
2011 30
2012 28
2013 32
2014 50
2015 27
2016 28
2017 17
2018 31
2019 7
2020 9
2021 11
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Results by year

Filters applied: . Clear all
Page 1
Diabetes and lipid metabolism.
Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, Karagiannis A. Athyros VG, et al. Hormones (Athens). 2018 Mar;17(1):61-67. doi: 10.1007/s42000-018-0014-8. Epub 2018 Apr 16. Hormones (Athens). 2018. PMID: 29858856 Review.
NAFLD and Statins.
Athyros VG, Katsiki N, Mikhailidis DP. Athyros VG, et al. Dig Dis Sci. 2020 Oct;65(10):3052-3053. doi: 10.1007/s10620-020-06505-x. Epub 2020 Aug 14. Dig Dis Sci. 2020. PMID: 32797344 No abstract available.
Pharmacological Management of Type 2 Diabetes Complications.
Doumas M, Imprialos K, Stavropoulos K, Athyros VG. Doumas M, et al. Among authors: athyros vg. Curr Vasc Pharmacol. 2020;18(2):101-103. doi: 10.2174/157016111802200101155519. Curr Vasc Pharmacol. 2020. PMID: 32013814 No abstract available.
Lipid-lowering treatment in peripheral artery disease.
Katsiki N, Giannoukas AD, Athyros VG, Mikhailidis DP. Katsiki N, et al. Among authors: athyros vg. Curr Opin Pharmacol. 2018 Apr;39:19-26. doi: 10.1016/j.coph.2018.01.003. Epub 2018 Feb 4. Curr Opin Pharmacol. 2018. PMID: 29413998 Review.
Inflammation and LDL Reduction.
Athyros VG, Sfikas G, Koumaras C. Athyros VG, et al. Curr Vasc Pharmacol. 2023;21(1):69-70. doi: 10.2174/1570161120666221004150503. Curr Vasc Pharmacol. 2023. PMID: 36200194 No abstract available.
Dysmetabolic Iron Overload in Metabolic Syndrome.
Sachinidis A, Doumas M, Imprialos K, Stavropoulos K, Katsimardou A, Athyros VG. Sachinidis A, et al. Among authors: athyros vg. Curr Pharm Des. 2020;26(10):1019-1024. doi: 10.2174/1381612826666200130090703. Curr Pharm Des. 2020. PMID: 32000639 Review.
Therapeutic options for statin-intolerant patients.
Kostapanos MS, Athyros VG, Karagiannis A, Mikhailidis DP. Kostapanos MS, et al. Among authors: athyros vg. Curr Med Res Opin. 2012 Mar;28(3):345-9. doi: 10.1185/03007995.2012.657757. Epub 2012 Jan 31. Curr Med Res Opin. 2012. PMID: 22292417 No abstract available.
Residual cardiac risk reduction beyond lipid lowering.
Pagourelias ED, Gossios TD, Tziomalos K, Karagiannis A, Geleris P, Athyros VG. Pagourelias ED, et al. Among authors: athyros vg. Hellenic J Cardiol. 2011 May-Jun;52(3):197-203. Hellenic J Cardiol. 2011. PMID: 21642067 Free article. Review. No abstract available.
393 results